A new non-surgical treatment for low-risk prostate cancer can effectively kill cancer cells while preserving healthy tissue, reports a new phase III clinical trial in 413 patients. The research found that around half (49 percent) of patients treated with VTP went into complete remission compared with 13.5 percent in the control group.